The Impact of Antibiotic Resistance on the Management of Infectious Diseases: A Systematic Review of Global Trends and Solutions

Abstract

Background: The widespread use of antibiotics in human healthcare, animal husbandry, and agricultural practices constitutes a major source of selective pressure that facilitates the emergence, persistence, and proliferation of antibiotic-resistant strains. Continuous exposure to antimicrobial agents promotes the survival of resistant microorganisms while suppressing susceptible populations, thereby accelerating the development and dissemination of antimicrobial resistance across diverse ecological and clinical environments. Aim: This systematic review intends to embark on an extensive analysis concerning the consequences of antimicrobial resistance (AMR) on the management of infectious diseases across the globe. This review will detail the most prominent resistance mechanisms associated with AMR and the most concerning pathogens. With regards to the epidemiological data across the WHO regions between the years of 1990 to 2021 with projections to the year 2050. This review will provide an analysis of the data for each individual region. Lastly, the existing and potential future interventions for AMR that have been documented between the years of 2000 to 2024. Study Design: A systematic review following PRISMA 2020 guidelines. Five databases including ;(PubMed/MEDLINE, Scopus, Web of Science, CINAHL, EMBASE) plus WHO, CDC, and ECDC grey literature were searched for studies published January 2000 to December 2024 reporting on AMR epidemiology, mechanisms, clinical outcomes, and interventions. Results: The prevalence of antibiotic resistance escalated in over 40% of monitored pathogen–antibiotic combinations from 2018 to 2023, with annual increments of 5–15%. Klebsiella pneumoniae resistance to 3rd-generation cephalosporins exceeded 55% globally and exceeded 70% in the WHO African Region. Antimicrobial resistance (AMR) was directly responsible for 1.27 million deaths and was associated with 4.95 million deaths from drug-resistant infections in 2019. Global antibiotic consumption increased 16.3% (29.5 to 34.3 billion DDDs) from 2016–2023. Antimicrobial stewardship programs (ASPs) achieved 20–30% reductions in antibiotic use. Forty-eight percent of countries failed to report to WHO GLASS in 2023. Without intervention, AMR is projected to cause 10 million deaths annually by 2050. Discussions: AMR is an escalating global emergency driven by antibiotic overuse, surveillance gaps, an insufficient drug development pipeline, and healthcare governance failures particularly in LMICs. Despite proven efficacy of ASPs, rapid diagnostics, and One Health surveillance frameworks, profound implementation inequities persist. A coordinated global response combining strengthened stewardship, accelerated R&D investment, regulatory reform of agricultural antibiotic use, and equitable access to diagnostics and treatment is urgently required to avert catastrophic AMR-related mortality and economic outcomes by 2050. Conclusion: The escalation of antibiotic resistance is being observed across countries worldwide and is driven by multiple interrelated factors, including the excessive and inappropriate use of antibiotics, inadequate surveillance systems, an insufficient pipeline for the development of new antimicrobial agents, and weaknesses in governance and regulatory frameworks. The burden of antimicrobial resistance is particularly severe in countries with limited healthcare infrastructure and lower adaptive capacity, where the need for effective antimicrobial interventions is often the greatest.